HighTower Advisors
FATE icon

HighTower Advisors’s Fate Therapeutics FATE Stock Holding History

HighTower Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.3K Sell
33,454
-1,868
-5% -$3.46K ﹤0.01% 3666
2026
Q1 		$42.4K Buy
35,322
+3,103
+10% +$3.78K ﹤0.01% 3720
2025
Q4 		$31.7K Sell
32,219
-4,981
-13% -$5.98K ﹤0.01% 3595
2025
Q3 		$46.9K Hold
37,200
– – ﹤0.01% 3616
2025
Q2 		$41.7K Buy
37,200
+27,000
+265% +$31.4K ﹤0.01% 3563
2025
Q1 		$8.06K Hold
10,200
– – ﹤0.01% 3565
2024
Q4 		$16.8K Sell
10,200
-400
-4% -$1.01K ﹤0.01% 3556
2024
Q3 		$37K Sell
10,600
-604
-5% -$2.35K ﹤0.01% 3444
2024
Q2 		$37K Buy
11,204
+104
+0.9% +$455 ﹤0.01% 3337
2024
Q1 		$81K Buy
11,100
+200
+2% +$1.24K ﹤0.01% 3192
2023
Q4 		$40K Sell
10,900
-5,071
-32% -$12K ﹤0.01% 3333
2023
Q3 		$33K Sell
15,971
-200
-1% -$663 ﹤0.01% 3273
2023
Q2 		$78K Sell
16,171
-485
-3% -$2.68K ﹤0.01% 3117
2023
Q1 		$94K Buy
16,656
+881
+6% +$5.32K ﹤0.01% 2961
2022
Q4 		$159K Sell
15,775
-1,694
-10% -$31.8K ﹤0.01% 2839
2022
Q3 		$391K Buy
17,469
+7,019
+67% +$203K ﹤0.01% 2187
2022
Q2 		$261K Sell
10,450
-7,911
-43% -$218K ﹤0.01% 2451
2022
Q1 		$714K Buy
18,361
+1,016
+6% +$39.3K ﹤0.01% 1956
2021
Q4 		$1.02M Buy
17,345
+4,182
+32% +$237K ﹤0.01% 1754
2021
Q3 		$779K Sell
13,163
-487
-4% -$38.2K ﹤0.01% 1795
2021
Q2 		$1.19M Buy
13,650
+7,098
+108% +$572K ﹤0.01% 1535
2021
Q1 		$540K Buy
+6,552
New +$628K ﹤0.01% 1926

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HighTower Advisors's FATE Position: Q2 2026 in Review

HighTower Advisors reduced its Fate Therapeutics (FATE) stake by 5.3% in Q2 2026, selling an estimated $3.46K and leaving 33,454 shares worth $90.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3666.

HighTower Advisors first reported a position in FATE in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.19M in Q2 2021. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • HighTower Advisors held 33,454 shares of Fate Therapeutics worth $90.3K as of Q2 2026.
  • HighTower Advisors sold 1,868 Fate Therapeutics shares in Q2 2026, an estimated $3.46K.
  • Fate Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3666 holding.
  • HighTower Advisors first reported a position in Fate Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • HighTower Advisors's Fate Therapeutics position peaked at $1.19M in Q2 2021.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.